Dublin, Feb. 13, 2017 -- Research and Markets has announced the addition of the "Handheld Devices for High Viscosity Injectables" report to their offering.
Growth in high viscosity drugs is being driven by advances in biotechnology and host-vector engineering - advances that have led to a steady stream of biologics for a number of ailments and conditions. These powerful drugs come with a high cost-per-dose and the risk of significant side effects - factors that place an elevated emphasis on administration efficiency, safety and reliability.
Many drugs in this class are characterized by physical properties and sensitivities that challenge the drug commercialization ecosystem. For example, monoclonal antibodies, perhaps the most significant category in terms of therapeutic and commercial importance, typically possess viscosities that are well above the normal limits of subcutaneous injection devices and techniques.
Without a technical solution, these high viscosity drugs are formulated and supplied for infusion, a trend that threatens to put additional pressure on patient logistics and healthcare economics. Drug developers and device designers are increasingly working in collaboration to address the goal of subcutaneous administration of high viscosity injectables.
Handheld Devices for High Viscosity Injectables - What You Will Learn
- What are the markets for therapeutic drugs with viscosities that cannot be delivered using standard self-injection devices and techniques?
- What are the technologies and devices that are aimed at positioning high viscosity drugs for subcutaneous injection?
- What are the design factors, material selection issues, formulation factors, and device capabilities and limitations of handheld devices that address the limitations of high viscosity drugs?
- Who are the high viscosity injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations?
- What are the key therapeutic sectors for high viscosity injectables?
- What does the market for high viscosity injectables look like today? What will it be in 2020?
- What is the impact of economic, technology, and regulatory factors on high viscosity drugs that can be administered via handheld devices?
Key Topics Covered:
1. Executive Summary
2. The Market Opportunity
3. High Viscosity Drug Market Dynamics
- The Economics of Drug Delivery
- Market Drivers
- Growth of Biological Drugs
- Demographics and Disease Prevalence
- Innovation in Handheld Devices
- Managed Care and Healthcare Economics
- Competitive Landscape
- Risk Factors
4. High Viscosity Injection Devices - Design Factors
- Drug Properties
- Drug Storage Requirements
- Baseline Device Capabilities
- Primary Packaging
- Human Engineering/Ergonomics
- Formulation Technology
5. High Viscosity Drugs - Addressable Markets
- Legacy Drugs - IV-to-Subcutaneous Migration
- Biologicals
- Drugs Currently Approved for Infusion
- Development-stage Biologicals
- Formulation-related High Viscosity
- Sustained Release Injectables
- Solubility-enhanced Formulations
6. Analysis of High Viscosity-Capable Handheld Devices
- Specialty Glass Syringes
- Specialty Autoinjectors
- Cyclic Olefin Prefillable Syringes
- Formulation-specific Devices
7. Near-term Therapeutic Sector Analysis
- Therapy Sectors
- Forecasts and Prospects
8. Market Factors
- Regulatory Issues
- Device Branding
- Quality by Design
- Ease of Use
9. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/km5gv3/handheld_devices
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Washington Post Publisher Will Lewis Steps Down After Layoffs
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



